October 21st 2021
Chan Cheah, MBBS, discusses TG-1701 as a more target-specific BTK inhibitor, the outcomes in response rates in the cohorts of the trial, and where future research is headed with this agent.
October 20th 2021
Sikander Ailawadhi, MD, discusses the unique pharmacodynamic profile of lisaftoclax, the similar responses seen across cohorts, and the favorable tolerability of the drug.
October 15th 2021
Marco Ruiz, MD, discusses the new HIV/Cancer Clinic and its goals, challenges faced with patients who have cancer and HIV infection, and clinical trial opportunities that strive to move the needle forward.
October 14th 2021
Toni Choueiri, MD, discusses key highlights from the 2021 Kidney Cancer Research Summit and exciting research efforts underway in renal cell carcinoma.
October 13th 2021
Alexey Danilov, MD, PhD, discussed the data on entospletinib/obinutuzumab in patients with R/R CLL and suggests further research directions with this drug combination.
October 7th 2021
Nadia Harbeck, MD, PhD, discusses the predictive impact of biomarkers on pathologic complete response and survival following de-escalated neoadjuvant T-DM1 with or without endocrine therapy in patients with hormone receptor–positive, HER2-positive breast cancer.
October 6th 2021
Tadeusz Robak, MD, discussed the 7-year safety and efficacy data from the RESONATE-2 trial examining frontline ibrutinib in CLL.
October 5th 2021
Bradley J. Monk, MD, FACS, FACOG, discusses the practice-changing data from KEYNOTE-826 examining pembrolizumab plus chemotherapy with or without bevacizumab and next steps for research in recurrent or metastatic cervical cancer.
October 4th 2021
Miranda Gogishvili, MD, discusses the rationale for examining cemiplimab plus platinum-doublet chemotherapy as a frontline treatment in patients with advanced NSCLC and key findings from the phase 3 EMPOWER-Lung 3 trial.
October 1st 2021
Brian A. Van Tine, MD, PhD, discusses the study design, key findings, adverse events, and research beyond the APROMISS study.
September 23rd 2021
Albiruni Ryan Abdul Razak, discusses the rationale for examining durvalumab with either olaparib or cediranib in patients with LMS, key data reported with this approach, and next steps for the phase 2 DAPPER study.
September 15th 2021
John C. Byrd, MD, discusses key findings from ELEVATE-RR, differences between acalabrutinib and ibrutinib, and future directions with the second-generation inhibitor.
August 30th 2021
Jennifer K. Litton, MD, discusses the rationale for examining neoadjuvant talazoparib in patients with BRCA1/2-positive, early HER2-negative breast cancer, safety and efficacy results from NEOTALA, and next steps for research.